Close
Almac
Achema middle east

BioAsia 2019 Life sciences 4.0 : Disrupt the disruption

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

BioAsia 2019 – the 16th edition of the widely attended annual convention, is all set to bring together the global industry leaders, researchers, policy makers, innovators, and investors together on one platform discussing the new opportunities in the transition.

BioAsia 2019, as a unique meeting platform for leaders from across the industry, will offer the right opportunities to catch the right notes and develop strategies to succeed in emerging markets like India. Join us during BioAsia 2019 and contribute to building an ecosystem that rewards all the stakeholders. This year at BioAsia 2019 we have more and unparalleled opportunities to learn and network than ever before.

Theme – Disrupt the disruption

 Healthcare is being reimagined globally as a result of scientific and technological advances. Ubiquity of mobile, peer-to-peer sharing tools, and experience of engaging personalized services in other areas of their lives (for e.g. retail and transportation industries) is changing consumers into super consumers. Pricing pressures are forcing Governments / healthcare authorities to prioritize better health outcomes at reduced costs. While true innovation will continue to be relevant, the government is increasingly promoting the prescription of generics and biosimilar.

Digital health start-ups and technology entrants are already moving aggressively into the mainstream by developing innovative and low cost products, services and solutions.

It is critical for all companies to invest strategically and differentially in the capabilities that create future value for all stakeholders. Life sciences companies in India, must determine how they can seize the upside of disruption in today’s transformative age to:

    Maintain leadership in the evolving generics industry
    Start gaining share in the biosimilars and personalized medicines market

BioAsia 2019 is themed on Life Sciences 4.0 where the global industry experts will share their thoughts on global trends and ramifications for all industry stakeholders viz. companies, policy makers, healthtech companies, startups, hospitals, scientists, etc.

We invite you to participate in the BioAsia 2019 conference and DISRUPT THE DISRUPTION!

  • 50+ Countries
  • 100+ High Profile Speakers
  • 800+ Corporates
  • 1000+ Partnering Meetings

Click here for more information:   http://2019.bioasia.in/

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »